According to the business intelligence report titled ‘Brazil Oncology Market Forecast 2027 By Cancer Type, By Cancer Diagnostics & Treatment, By End-use, Research Report, COVID-19 Impact Statistics, Country Outlook, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share’, available with Market Study Report, Brazil oncology market is anticipated to be worth USD 16.5 billion valuation by 2027.
 

Increasing incidence of cancer and associated conditions like obesity, efforts by government and worldwide organizations to raise awareness about the disease, and technological developments are the key growth stimulants for Brazil oncology market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3963059/
 

As per the World Health Organization, 600,000 cases of cancer were recorded in Brazil between October and December 2020. Further, over 1.5 million cases are anticipated to be registered by 2030, indicating a strong demand for treatment in the upcoming years. Besides, strategic initiatives undertaken by WHO in tandem with the country’s universal coverage system SUS, which provides treatments to hospitalized patients free of cost, will also aid revenue inflow in the upcoming years.
 

For the unversed, oncology is a discipline which studies cancer, its diagnosis, therapy, and prevention. It is subdivided into three types – medical oncology, surgical oncology, and radiation oncology. Medical oncology refers to cancer treatment using medicines and its scope includes chemotherapy. Whereas, surgical oncology involves staging, biopsy, and surgical removal of tumors. Speaking of radiation oncology, it involves the treatment with therapeutic radiation.
 

While the rising presence of patient-centric diagnostic centers will facilitate the growth of oncology industry in Brazil, severe risks associated with high radiation exposure and its impact on use of CT scanners, along with imbalances in the healthcare system will act as challenges for businesses in this domain.  
 

Based on cancer type, breast cancer segment is anticipated to attain a value of USD 3.3 billion by 2027 owing to surging incidence of this cancer form as a result of obesity, age related hazards, and hormone imbalance. In fact, approximately 66,280 new cases of breast cancer were estimated to be recorded in Brazil in 2020, which is 29.7% of the total number of cases.
 

Speaking of end-use spectrum, private segment held majority of the industry share in the recent past and garnered USD 4.9 billion in 2020.
 

Key players shaping Brazil oncology market dynamics are Pfizer Inc., Abbott Laboratories, Merck & Co. Inc., Bayer AG, AstraZeneca plc, Biocartis Group N.V., Amgen Inc., Bio-Rad Laboratories Inc., Tesaro Inc. (GlaxoSmithKline plc), Cancer Genetics Inc., Thermo Fisher Scientific Inc., GE Healthcare, Sysmex Corporation, Kite Pharma (Gilead Sciences Inc.), Siemens Healthineers AG, Janssen Diagnostics LLC (Johnson & Johnson), F. Hoffmann La Roche AG, and BioMérieux SA.